Afrin Spray
NDC Package 11523-1167-2

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Afrin (oxymetazoline hydrochloride) sprays is a medication used for temporary relief of congestion in the nose caused by various conditions including the common cold, sinusitis, hay fever, and allergies. This formulation utilizes a spray delivery system. Marketed by Bayer Healthcare Llc., this product is identified by NDC 11523-1167 and is authorized under FDA application M012.

Identification & Billing

NDC Package Code
11523-1167-2
Package Description
2 BOTTLE, SPRAY in 1 CARTON / 21 mL in 1 BOTTLE, SPRAY
Product Code
11-Digit Billing Format
11523116702
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Afrin Original
Non-Proprietary Name
Oxymetazoline Hydrochloride
Substance Name
Oxymetazoline Hydrochloride
Dosage Form
Spray - A liquid minutely divided as by a jet of air or steam.
Administration Route
Nasal - Administration to the nose; administered by way of the nose.
Usage Information
This medication is used for temporary relief of congestion in the nose caused by various conditions including the common cold, sinusitis, hay fever, and allergies. It works by narrowing the blood vessels in the nose area, reducing swelling and congestion.

Regulatory & Marketing

Labeler Name
Bayer Healthcare Llc.
Product Type
Human Otc Drug
FDA Application #
M012
Marketing Category
OTC MONOGRAPH DRUG -
Start Marketing Date
07-14-1975
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (11523-1167). Click a package code to view its specific billing and regulatory data.

6 mL in 1 BOTTLE, SPRAY
1 BOTTLE, SPRAY in 1 CARTON / 20 mL in 1 BOTTLE, SPRAY
3 BOTTLE, SPRAY in 1 CARTON / 30 mL in 1 BOTTLE, SPRAY
1 BOTTLE, SPRAY in 1 CARTON / 30 mL in 1 BOTTLE, SPRAY
1 BOTTLE, SPRAY in 1 CARTON / 15 mL in 1 BOTTLE, SPRAY

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 11523-1167-2 identifies a specific commercial package of 2 bottle, spray in 1 carton / 21 ml in 1 bottle, spray of Afrin Original, a human over the counter drug labeled by Bayer Healthcare Llc.. This spray is formulated for nasal use and contains oxymetazoline hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bayer Healthcare Llc. on July 14, 1975. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used for temporary relief of congestion in the nose caused by various conditions including the common cold, sinusitis, hay fever, and allergies. It works by narrowing the blood vessels in the nose area, reducing swelling and congestion.

How is this Bayer Healthcare Llc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 11523116702. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
11523-1167-2
11-Digit CMS (5-4-2)
11523-1167-02

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.